Stocks To Buy Now

Blog


On the Move Systems, Inc. (OMVS) Aims to Help Retailers Solve “Last Mile” Problem

On the Move Systems today issued a press release to shine light on the problem of retailers investing millions of dollars in technology to ensure prompt order fulfillment only to see their efforts ruined by poor delivery service in the shipment’s “last mile,” leaving upset customers and destroying business relationships. On the Move Systems is focused on helping retailers fix that problem with its proposed shared economy courier service that promises not only fast, on-demand delivery, but professional, courteous service that will set it apart from traditional competition.

Amazon and Wal-Mart are two large retailers that realize the long-term value of providing fast, affordable last-mile solutions that satisfy customers’ expectations and add to the corporate bottom line. Each company is investing heavily to make sure their customers can not only get their online orders in the shortest possible time, but that those customers receive them in a way that leads to repeat business down the road.

“Wal-Mart and Amazon can afford to invest the millions to ensure last-mile satisfaction from the customer, but what about smaller retailers?” said OMVS CEO Robert Wilson. “Our on-demand courier business can help smaller retailers match Amazon’s and Wal-Mart’s speed, efficiency and service, putting them on an even footing with the giants. We expect there to be great demand for this, especially as the holiday season approaches and shippers face increasing lag times.”

Estimates peg the value of large last mile shipments at $8 billion annually, with the value of smaller shipments much higher. Retail industry analysts predict that companies that can best leverage last-mile solutions will be able to drive top-line growth and reap profits.

For more information on OMVS, please visit www.onthemovesystems.com

Let us hear your thoughts: On the Move Systems Corp. Message Board

From Our Blog

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Has the World’s Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes

March 31, 2026

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is in the unique position of holding the world’s only clinical-stage protein phosphatase 2A (“PP2A”) inhibitor, called LB-100. The LB-100 compound is a proprietary small-molecule PP2A inhibitor that is designed to target protein phosphatase 2A (“PP2A”), introducing a potential new treatment paradigm aimed at enhancing existing […]

Rotate your device 90° to view site.